| abstract |
The invention provides compositions for selectively inhibiting the binding of integrin α4β7 to the cell mucosal adhesion molecule adressin-1 (MAdCAM-1), containing a mixture of non-reducing sugar, anti-α4β7 antibody and at least one free amino acid. These compositions have improved stability, reduced formation of aggregates of antibodies and in them the degradation of antibodies is slowed down. The present invention also provides a safe dosage regimen of the compositions, which is easy to implement and provides a therapeutically effective amount of anti-α4β7 antibodies in vivo. |